Literature DB >> 22166461

Mood disorders in Parkinson's disease.

Louis C S Tan1.   

Abstract

An increasing emphasis has been placed on the identification and management of non-motor features of Parkinson's disease (PD). Of the behavioural disorders in PD, mood disorders are amongst the most common and can occur in both early and late stages of PD. In some cases, these problems may even precede the development of motor symptoms of PD. These disorders have a major impact in the quality of life and affect daily function. This review will focus on depression, anxiety and apathy, and will discuss the epidemiological, clinical features, diagnosis and management of these disorders. The diagnosis and evaluation of these problems remain a challenge in view of the overlapping symptoms between these disorders and also with the clinical features of PD. The development and validation of diagnostic criteria and rating scales for these disorders remain a priority particularly in relation to anxiety and apathy. Another gap in the management of these disorders is the limited empirical evidence for the treatment of these problems. There is therefore an urgent need for systematic studies in the pharmacological and non-pharmacological management of these disorders to enable a holistic and evidence-based approach to the management of mood disorders in PD.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22166461     DOI: 10.1016/S1353-8020(11)70024-4

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  20 in total

Review 1.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

2.  Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity.

Authors:  Milos Stanojlovic; Jean Pierre Pallais Yllescas; Aarthi Vijayakumar; Catherine Kotz
Journal:  Mol Neurobiol       Date:  2019-06-27       Impact factor: 5.590

Review 3.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 4.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

5.  Use of the World Health Organization Quality of Life Assessment Short Version in Mild to Moderate Parkinson Disease.

Authors:  Sarah K Hendred; Erin R Foster
Journal:  Arch Phys Med Rehabil       Date:  2016-06-23       Impact factor: 3.966

6.  Affective disorders in Parkinson's disease.

Authors:  Kelly S G Aminian; Antonio P Strafella
Journal:  Curr Opin Neurol       Date:  2013-08       Impact factor: 5.710

7.  Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease.

Authors:  Milos Stanojlovic; Jean Pierre Pallais; Michael K Lee; Catherine M Kotz
Journal:  Mol Brain       Date:  2019-10-30       Impact factor: 4.041

8.  The 10-year Landscape of United States-Registered Parkinson Disease Clinical Trials: 2007-2016.

Authors:  Kara J Wyant; Erika Yasuda; Vikas Kotagal
Journal:  Mov Disord Clin Pract       Date:  2018-10-04

9.  Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects.

Authors:  Anne Marie Bonnet; Marie France Jutras; Virginie Czernecki; Jean Christophe Corvol; Marie Vidailhet
Journal:  Parkinsons Dis       Date:  2012-07-25

Review 10.  Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?

Authors:  Jean-François Daneault; Benoit Carignan; Abbas F Sadikot; Michel Panisset; Christian Duval
Journal:  BMC Med       Date:  2013-03-20       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.